NASDAQ:IVA Inventiva Q4 2025 TU Earnings Results & Report $2.92 +0.06 (+1.92%) As of 11:47 AM Eastern This is a fair market value price provided by Massive. Learn more. Inventiva reported Q4 2025 TU earnings on February 15, 2026. The company reported EPS of -$0.16, while revenue was $0.01 million. Research:ProfileEarnings HistoryForecast Earnings Announcement Details QuarterQ4 2025 TUReport DateFebruary 15, 2026TimeBefore Market OpensConference Call DateFebruary 16, 2026Conference Call11:45 AM ET Inventiva EPS ResultsActual EPS-$0.16Consensus EPS N/ABeat/MissN/AOne Year Ago EPSN/AInventiva Revenue ResultsActual Revenue$0.01 millionExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/AConference Call ResourcesPress ReleaseEarnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release Inventiva Q4 2025 TU Earnings FAQ Did Inventiva beat earnings estimates for Q4 2025 TU? Inventiva (NASDAQ:IVA) reported earnings of -$0.16 per share for Q4 2025 TU. The report was announced on Sunday, February 15, 2026. What was Inventiva's revenue for Q4 2025 TU? Inventiva reported revenue of $0.01 million for Q4 2025 TU. Inventiva Earnings HeadlinesInventiva: Significant Upside Potential Ahead Of Pivotal Liver Disease ReadoutOctober 14 at 4:00 AM | seekingalpha.comInventiva to Present Scientific Abstracts at AASLD The Liver Meeting® 2026October 6, 2026 | finance.yahoo.comHow one AI fund pays investors every ThursdayOne small fund tied to artificial intelligence stocks delivered $1,051 in a single month, not through selling shares or trading options, but simply by holding the fund and letting it pay out cash every Thursday. That works out to a 34% annualized distribution rate, even though the underlying AI stocks pay no dividends themselves. Tim Plaehn, Chief Income Strategist at Investors Alley, breaks down exactly how the fund generates these weekly payouts.October 14 at 1:00 AM | Investors Alley (Ad)Inventiva (IVA): How Much Is One Make-or-Break Readout Really Worth?October 4, 2026 | finance.yahoo.comTruist Financial Forecasts Strong Price Appreciation for Inventiva (NASDAQ:IVA) StockOctober 4, 2026 | americanbankingnews.comInventiva (NASDAQ:IVA) Sees Large Volume Increase After Analyst UpgradeOctober 4, 2026 | americanbankingnews.comSee More Inventiva Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Inventiva? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Inventiva and other key companies, straight to your email. Email Address About InventivaInventiva (NASDAQ:IVA) S.A. is a clinical-stage biopharmaceutical company headquartered in Daix, France. Founded in 2011, the company focuses on developing oral treatments for metabolic dysfunction-associated steatohepatitis (MASH), a serious form of fatty liver disease associated with metabolic disorders. Inventiva's lead drug candidate is lanifibranor, an investigational pan-peroxisome proliferator-activated receptor (pan-PPAR) agonist being evaluated in the Phase 3 NATiV3 clinical trial. The company expects topline trial results in Q4 2026 and, if results are positive, plans to pursue U.S. regulatory approval, with a potential commercial launch in 2028. Inventiva was founded by former Abbott Laboratories executives and became a French public limited company in 2016. Its American Depositary Shares trade on the Nasdaq Global Market under the symbol IVA, while its ordinary shares are listed on Euronext Paris. The company is led by Chief Executive Officer Andrew Obenshain, who succeeded co-founder Frédéric Cren in October 2025. View Inventiva ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles A Chinese Rival Just Spooked Memory Stocks—How Worried Should Micron Investors Be?PepsiCo's Earnings Beat Masks a Bigger Problem With Its North American BusinessTax Credit Turmoil: Why Enphase and SolarEdge Face a Tough RoadSurgical Precision, Sustainable Returns: Johnson & Johnson Secures Its Cash Flow RunwayJPMorgan Earnings Miss Estimates But Reveal Broad-Based StrengthAmazon's $220 Billion AI Bet Is Getting Bigger—Can Earnings Justify the Spending?Venezuela's Oil Revival Is Gaining Momentum—3 Energy Stocks Positioned to Benefit Upcoming Earnings Interactive Brokers Group (10/15/2026)Marsh & McLennan Companies (10/15/2026)The PNC Financial Services Group (10/15/2026)Charles Schwab (10/15/2026)U.S. Bancorp (10/15/2026)Prologis (10/15/2026)Taiwan Semiconductor Manufacturing (10/15/2026)Truist Financial (10/16/2026)Travelers Companies (10/16/2026)HDFC Bank (10/17/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
